Patterson Companies Declares Quarterly Dividend

ST. PAUL, Minn.--(BUSINESS WIRE)--The Board of Directors of Patterson Companies, Inc. (Nasdaq: PDCO), today declared a quarterly cash dividend of $0.20 per share. The dividend will be payable on January 23, 2015, to shareholders of record as of January 9, 2015.

"I am once again happy to announce our quarterly dividend, which demonstrates our board's confidence in the company's strategic direction and growth initiatives," said Scott P. Anderson, chairman and chief executive officer. "This marks Patterson's 20th consecutive quarterly cash dividend. We remain committed to following a disciplined approach to returning capital to our shareholders and delivering long-term value."

About Patterson Companies, Inc.
Patterson Companies, Inc. is a value-added distributor serving the dental, companion-pet veterinarian and rehabilitation supply markets.

Dental Market
As Patterson's largest business, Patterson Dental provides a virtually complete range of consumable dental products, equipment and software, turnkey digital solutions and value-added services to dentists and dental laboratories throughout North America.

Veterinary Market
Patterson Veterinary is a leading distributor in the U.S. and U.K. of consumable veterinary supplies, equipment and software, diagnostic products, vaccines and pharmaceuticals predominantly to companion-pet veterinary clinics.

Rehabilitation Market
Patterson Medical is the world's leading distributor of rehabilitation supplies and non-wheelchair assistive patient products to the physical and occupational therapy markets. The unit's global customer base includes hospitals, long-term care facilities, clinics and dealers.

Contacts
Patterson Companies, Inc.
Ann B. Gugino, 651-686-1600
Vice President & CFO

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…